Overview

Bazedoxifene -Treatment for Women With Schizophrenia

Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
To study the effect of adjunctive bazedoxifene - a selective estrogen receptor modulator (SERM) in a double blind, placebo-controlled adjunctive study in the treatment of women with schizophrenia. All patients receive standardized antipsychotic medication.
Phase:
Phase 4
Details
Lead Sponsor:
The Alfred
Collaborators:
Monash Health
Monash University
Treatments:
Bazedoxifene